Spruce Biosciences, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for SPRB, updated each market day.
SPRB AI Sentiment
AI sees no strong directional signal for Spruce Biosciences, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Spruce Biosciences, Inc. Common Stock
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
Sector
Exchange
Market Cap
$90,568,558
Cap Tier
Employees
8
Headquarters
SOUTH SAN FRANCISCO, CA
Listed Since
Oct. 9, 2020
SPRB Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
SPRB Volatility
Spruce Biosciences, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
